Hypolipidemic agent. Exhibits higher potency than nicotinic acid and clofibrate. Full and potent agonist at the human orphan GPCR HM74A/GPR109A and GPR109B (EC50 values are 1.3 and 4.2 μM respectively). Reduces serum triglycerides and circulating LDL-cholesterol in vivo, without affecting liver weight or liver enzymes.